Pelthos Therapeutics (NYSEAMERICAN:PTHS) Upgraded at Zacks Research

Zacks Research upgraded shares of Pelthos Therapeutics (NYSEAMERICAN:PTHS) from a strong sell rating to a hold rating in a research report report published on Tuesday morning,Zacks.com reports.

A number of other research firms have also recently weighed in on PTHS. Roth Mkm dropped their target price on shares of Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Oppenheimer raised their price target on shares of Pelthos Therapeutics from $60.00 to $62.00 and gave the stock an “outperform” rating in a research note on Friday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Finally, Piper Sandler assumed coverage on Pelthos Therapeutics in a research note on Friday, February 27th. They issued an “overweight” rating and a $48.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.25.

Pelthos Therapeutics Stock Performance

PTHS opened at $22.74 on Tuesday. The company has a market capitalization of $76.41 million, a price-to-earnings ratio of -1.10 and a beta of 3.87. The firm’s 50-day moving average is $23.14. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.15 and a current ratio of 2.05. Pelthos Therapeutics has a fifty-two week low of $9.00 and a fifty-two week high of $54.29.

Institutional Trading of Pelthos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in PTHS. Persistent Asset Partners Ltd grew its holdings in Pelthos Therapeutics by 150.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after buying an additional 3,604 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Pelthos Therapeutics in the fourth quarter worth about $343,000. Geode Capital Management LLC boosted its position in shares of Pelthos Therapeutics by 31.9% in the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after acquiring an additional 3,295 shares during the period. Knott David M Jr boosted its position in shares of Pelthos Therapeutics by 215.5% in the fourth quarter. Knott David M Jr now owns 19,281 shares of the company’s stock valued at $598,000 after acquiring an additional 13,169 shares during the period. Finally, Diadema Partners LP grew its stake in Pelthos Therapeutics by 138.1% during the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after acquiring an additional 14,502 shares in the last quarter. Hedge funds and other institutional investors own 77.96% of the company’s stock.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).